Abstract Cardiac atrial natriuretic peptide (ANP) locally counteracts cardiac hypertrophy via the guanylyl cyclase-A
Introduction
Cardiac atrial natriuretic peptide (ANP) lowers arterial blood pressure and intravascular volume by a combination of direct and indirect effects that involve vasodilatation, increases in endothelial permeability, stimulation of renal function, and inhibition of the sympathetic as well as renin-angiotensinaldosterone (RAA) systems [25, 26] . These actions of ANP are mediated by a membrane-bound guanylyl cyclase (GC) receptor, GC-A, which mediates increases in intracellular cyclic GMP levels in response to ANP binding [25, 26] . Mice with global disruption of the GC-A gene (GC-A-/-mice) not only have increased systemic arterial blood pressure but also display a marked cardiac hypertrophy which is disproportionate to their increased blood pressure and partly resistant to antihypertensive medication [23, 28] . Extending these studies, our own observations in mice with conditional, cardiomyocyte-restricted deletion of GC-A (CM GC-A KO mice) demonstrated that ANP, via GC-A/cGMP signalling, exerts important local, auto/paracrine functions to moderate pathological cardiomyocyte growth [18] . The intracellular signalling pathways mediating the local antihypertrophic effects of ANP/GC-A are unknown. Because patients with essential hypertension and/or cardiac hypertrophy/insufficiency exhibit diminished systemic and cardiac responsiveness to ANP [25, 26] , clarification of this issue is important from a physiological and also pathophysiological perspective.
On the opposite, the RAA system enhances arterial blood pressure and volume. Angiotensin II (Ang II) is a potent vasoconstrictor, it increases sympathetic tone and exerts indirect antidiuretic and antinatriuretic actions via stimulation of aldosterone and antidiuretic hormone (ADH) secretion [21] . Besides these systemic actions, locally produced Ang II exerts direct trophic actions within the heart, inducing cardiomyocyte hypertrophy, fibroblast proliferation and interstitial fibrosis, thereby contributing to pathologic cardiac remodelling [4, 32, 40] . Both the hypertensive and cardiac hypertrophic as well as profibrotic actions of Ang II are mediated through the Ang II type 1 (AT 1 ) receptor [4, 37, 39] .
Importantly, ANP counter regulates not only the systemic but also the cardiac effects of the RAA system. It inhibits renin release and Ang II-stimulated aldosterone production [29, 31] and antagonizes the vasoconstrictor, sympathotonic, and antinatriuretic actions of Ang II [22] , but also inhibits trophic effects of Ang II on cultured cardiac myocytes and fibroblasts [9] . Thus, the physiological balance between the ANP/GC-A and Ang II/AT 1 systems is not only involved in the endocrine maintenance of arterial blood pressure and intravascular volume homeostasis, but also in the local, paracrine regulation of cardiac growth.
Cardiac myocytes respond to increased mechanical work-load or to neurohumoral stressors, such as Ang II by altering the frequency and amplitude of their calcium transients [1, 8, 16] . Encoded in these calcium responses are signals that, at difference to b-adrenergic stimulation, alter not only immediate contractility, but also initiate and maintain a remodelling response that adjusts cellular mass, ionic currents, kinetic properties of contractile proteins, and metabolic capacity [16] . Persistence of these signals modulates the calcium signalling events resulting in a hypertrophic response and adverse remodelling. Recent work indicates that hypertrophic agonists linked to Gaqprotein coupled receptors such as Ang II activate calcium entry through transient receptor potential canonical (TRPC) channels [34] and that these channels, especially TRPC1, C3 and C6, can trigger pathologic, hypertrophic calcium signalling in the heart [34, 41] . In contrast, physiological (e.g. exercise-induced) or b-adrenergic modulation of myocyte calcium and growth apparently does not involve TRPC channels. However, this hypothesis is mostly based on the work with cultured neonatal rat myocytes [34] , which exhibit important structural, biochemical and functional differences to adult cardiac myocytes.
To gain new insights into the intracellular signalling pathways mediating the local antihypertrophic effects of ANP/GC-A, we compared the influence of ANP on b-adrenergic versus Ang II-dependent (G s vs. G aq mediated) modulation of Ca 2?
i handling in cardiomyocytes and of cardiac hypertrophy in mice. The results demonstrate the role and functional compartmentation of cGMP and cGMPdependent protein kinase type I (PKG I) stimulation by ANP in the heart. They also emphasize that TRPC3/TRPC6 channels are essential for the increase of [Ca 2? ] i in adult myocytes by Ang II, but not by isoprenaline.
Materials and methods

Genetic mouse models
Mice with conditional, cardiomyocyte-restricted deletion of the GC-A receptor (CM GC-A KO mice) and control littermates (floxed GC-A mice, with normal GC-A expression levels) were generated and genotyped as described [18] . Transgenic mice with genetic deletion of PKG I [49] , regulator of G protein signalling (RGS)-2 [15] or TRPC3/C6 channels and respective control mice were obtained from collaborating laboratories. The PKG I mutants were so-called SM-Ib rescue mice [49] i transients together with simultaneously recorded cell length were measured in INDO-1 loaded, electrically paced (0.5 Hz) cardiomyocytes as described before [20] . Excitation was at 365 nm, and the emitted fluorescence was recorded at 405 and 495 nm. The ratio of fluorescence at the two wavelengths was used as an index of the cytosolic Ca 2? concentration. Data were collected at 20 Hz, and acquisition and processing were supported by Felix software (Felix version 1.1, Photon Technologies, Seefeld, Germany) [20] . After obtaining basal recordings for 10 min, myocytes were exposed to Ang II (10 nM) or isoproterenol (ISO, 100 nM; both Sigma, Taufkirchen, Germany) in the presence or absence of ANP (mouse ANP, 100 nM; Bachem, Heidelberg, Germany) (superfusion of cardiomyocytes with ANP or vehicle during 10 min; then superfusion with Ang II or ISO in the presence of ANP during additional 10 min).
Electrophysiological recordings on ventricular myocytes
Single cardiomyocytes were studied using the whole-cell configuration of the patch-clamp technique [24] . For recordings, cells were plated in a small dish (2 cm Ø) on the stage of an inverted microscope (Leica, Cologne, Germany) directly before the start of the measurements. [24] .
Effect of ANP/PKG I on expression and subcellular localization of RGS2 in HEK 293 cells Human embryonic kidney (HEK)-293 cells stably expressing GC-A were transiently cotransfected with cDNAs coding for human regulator of G protein signalling (RGS) 2 and PKG Ia using FuGENE reagent according to manufacturer 0 s instructions (Roche, Mannheim, Germany). After 2 days of transfection, the cells were treated with ANP (10 nM) or vehicle for the indicated time. For separation of the cytosolic, membrane, and nuclear proteins, a cell fractionation kit was applied (nano-TOOLS Antikör-pertechnik, Teningen, Germany). SDS-PAGE and immunoblotting were performed as previously described [12] . Antibodies were against GC-A [12], PKG I [48] , RGS2 (ProteinTech Group, Chicago, USA) and GAPDH. The blots were developed using the ECL detection system (Amersham-Pharmacia, Freiburg, Germany) and the results were quantitated by densitometry (ImageQuant) [12, 20] .
Chronic treatment of mice with Ang II or ISO Control and CM GC-A KO mice were infused subcutaneously with vehicle, Ang II (250 ng/kg BW/min, 2 weeks) or ISO (40 mg/kg BW/day, 7 days [5] ) via osmotic minipumps (model 2002; Alzet, Colorado City, CO). Male and female mice 4-6 weeks old were examined (n = 8-12 mice per group). Arterial blood pressure was measured in conscious mice of the three treatment groups by tail cuff (Softron, Tokyo, Japan) [18, 20] . Mice were then killed under urethane anesthesia, the hearts were weighed and the Basic Res Cardiol (2010) 105:583-595 585 left ventricles were bisected and frozen in liquid nitrogen (for protein extraction) and fixed in 4% buffered formaldehyde (for histology).
Histology
For histological analysis, formaldehyde-fixed left ventricles were embedded in paraffin, and 5-lm sections were stained with hematoxylin eosin or periodic acid Schiff (PAS, to discriminate cardiomyocyte cell borders) [18, 20] . Photomicrographs of the sections were evaluated using the computer-assisted image analysis system Cell-D (Olympus, Hamburg Germany), with the investigator blinded to the genotypes. The mean cross-sectional cardiomyocyte diameters were calculated by measuring 100 cells with a centrally located nucleus per specimen.
Western-blot analyses
Left ventricular proteins were solubilized in SDS-sample buffer and separated by 10% PAGE. The primary antibodies were against CaMKII (BD Transduction Laboratories) and autophosphorylated (active) CaMKII (Santa Cruz). GAPDH was used to control equal loading. The blots were developed using the ECL detection system and the results were quantitated by densitometry.
Statistics
The results are presented as mean ± SEM. Group data were compared using one-way or two-way ANOVA (with genotype and treatment as categories) followed by the multiple comparison Bonferroni t test to assess differences between groups. The significance level was set at P \ 0.05. i transients (Fig. 1a, b) . The responses were accompanied by increased sarcomere shortening (Fig. 1c, d ). The exposure of isolated myocytes to 100 nM ANP did not change the resting Ca 2?
Results
ANP inhibits the Ca
i transient or basal sarcomere shortening (Fig. 1a-d ). However, ANP had very different effects on the responses to ISO and Ang II. Calcium and shortening responses to Ang II were totally prevented by ANP (100 nM, 10-min pretreatment) (Fig. 1a, c) . In contrast, ANP did not affect calcium and shortening responses to ISO (Fig. 1b, d ).
This disparity was further revealed in electrophysiological recordings of L-type Ca 2? currents. Currents through L-type Ca 2? channels were measured using the patch-clamp technique in the whole-cell configuration. Ang II (10 nM) and ISO (100 nM) both acutely amplified Ca 2? current densities ( Fig. 2a-d) . ANP (100 nM) alone did not affect L-type Ca 2? current densities (Fig. 2b, d ). Pretreatment with ANP fully inhibited Ang II-stimulation of L-type Ca 2? channel activity ( Fig. 2b ) and had no effect on ISO-stimulation of L-type Ca 2? channel activity (Fig. 2d ). Taken together, these experiments demonstrate that ANP selectively inhibits the myocyte calcium responses to Ang II, but not to b-adrenergic stimulation. responses of GC-A-deficient myocytes to Ang II were not altered by ANP (Fig. 3a) . We conclude that GC-A/cGMP signalling mediates the counteraction of myocyte Ca 2? responses to Ang II by ANP. Several cGMP-modulated proteins are expressed in myocytes, such as phosphodiesterases (PDE 2, 3 and 9) and PKG I [47] . To investigate the possible contribution of PKG I, we took advantage of a genetic smooth muscle rescue mouse model that lacks expression of PKG I in cardiomyocytes (mouse genotype: PKG I L-/L-;SM-Ib ?/-; PKG I -/-myocytes) [49] . As shown in i transients and calcium responses to Ang II were in PKG I -/-like in respective control myocytes. However, while in respective control myocytes the stimulatory effects of Ang II were fully abolished in the presence of ANP, in PKG I -/-myocytes ANP pretreatment could not prevent the calcium-stimulating effects of Ang II (Fig. 2b) . Corroborating these findings, the inhibitory effects of ANP in control myocytes were completely prevented by the selective PKG I inhibitor Rp-8-Br-PET-cGMP (10 lM, pretreatment for 30 min before addition of ANP and Ang II; Biolog, Hamburg, Germany), confirming PKG I-mediated effects (Fig. 3b) .
Our observation that the ANP/GC-A/cGMP/PKG I pathway inhibits the myocyte Ca 2? responses to Ang II but not to ISO, seemed to indicate a selective modulation of G aq/11 -coupled receptor signalling. The regulator of G protein signalling (RGS)-2 is a selective and negative regulator of G q/11 proteins in the cardiovascular system which is activated by PKG I [51] . To study whether RGS2 mediates effects of ANP, we compared myocytes from RGS2-deficient mice and controls [15] . Because 10 nM Ang II often provoked arrhythmias in RGS 2 -/-myocytes (not shown), instead we studied their responses to 1 nM Ang II. As shown in Fig. 3c , the calcium responses of RGS 2-deficient myocytes to 1 nM Ang II were greater as the responses of respective wild-type myocytes (controls) to 10 nM Ang II. The calcium and shortening responses of
RGS2
-/-myocytes to ISO were unaltered (not shown). Fig. 5a ). Hypertensive reactions were similar in mice from both genotypes. In contrast, ISO essentially had no effect on blood pressure (Fig. 5a) . In both genotypes, chronic administration of Ang II or of ISO led to significant cardiac hypertrophy, as demonstrated by the increases in the left ventricular (LV) weight -to -body weight (BW) ratios (Fig. 5b ) and the enlargement of LV myocyte diameters (Fig. 5c) . Notably, these effects of Ang II on cardiac remodeling were more pronounced in CM GC-A KO mice than in controls (Fig. 5b, c) , despite the similar hypertensive reactions. In contrast, the hypertrophic effects of ISO were not different between genotypes (Fig. 5b, c) .
We conclude from these in vivo data that a chronic inhibition of the local, cardiac effects of ANP exacerbates the hypertrophic actions of Ang II, but not of b-adrenergic stimulation.
Enhanced Ang II-induced cardiac hypertrophy in CM GC-A KO mice is accompanied by greater activation of the Ca 2? /calmodulin-dependent kinase II pathway
Because increases in cytoplasmic Ca 2? can induce cardiomyocyte hypertrophy through Ca 2? /calmodulin-mediated activation of CaMKII signalling [30] , we assessed the activity of this pathway. The cardiac left ventricular expression of total CaMKII was not different between genotypes and/or treatment groups (Fig. 6 top) . However, Fig. 6a, b) . In control mice chronic Ang II or ISO treatment significantly increased cardiac CaMKII autophosphorylation. The effect of Ang II was markedly enhanced in CM GC-A KO mice (Fig. 6a) . In contrast, ISO treatment did not further increase pCaM-KII levels in hearts of CM GC-A KO mice (Fig. 6b) i responses of adult cardiomyocytes to Ang II are mediated by TRPC3/C6 activation, first, we studied the calcium responses to Ang II in adult cardiomyocytes from double KO mice with genetic deletion of both TRPC3 and TRPC6 (TRPC3 -/-/C6 -/-) [3, 11] . As shown in Fig. 7a-d (Fig. 8a, b) were completely absent in TRPC3
-/-/C6 -/-cardiomyocytes. In contrast, the effects of ISO (100 nM) on Ca (Fig. 7b) and L-type Ca 2? currents (Fig. 8c, d) were not different between genotypes. Corroborating these observations, in control myocytes the inhibition of TRPC channel activity with the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2 (2 lM; Calbiochem [13] ), fully abolished the stimulatory effects of Ang II on Ca 2? i transients (Fig. 7c) and did not alter the effects of ISO (Fig. 7d) .
Discussion
Major findings
The present studies in vivo and in isolated myocytes show essentially that the ANP/GC-A/cGMP pathway counter regulates cardiac Ang II, but not b-adrenergic stimulation of calcium handling, of the calcium-dependent prohypertrophic CaMKII pathway and of cardiac hypertrophy. The mechanism behind this differential regulation of the Ang II versus ISO responses by ANP involves PKG I and the regulator of G protein signalling (RGS) 2, a major target of PKG I, because the inhibitory effects of ANP on the Ca signalling and activation of RGS2, specifically counter regulates the hypertrophic effects of agonists linked to Gaqprotein coupled receptors, such as Ang II. In contrast, ANP does not affect b-adrenergic modulation of cardiac calcium handling and myocyte growth. Lastly, our study extents and strengthens previously published observations in neonatal cardiomyocytes [34] demonstrating for the first time that transient receptor potential canonical TRPC3/C6 channels are indispensable for the calcium responses of adult myocytes to Ang II and are not involved in calcium responses to b-adrenergic stimulation.
Differential regulation of cardiac Ang II, but not b-adrenergic responses by ANP Our results are in accordance with previous studies showing that cardiac remodeling in mice with global (not cardiomyocyte specific) GC-A disruption is markedly inhibited by genetic or pharmacological blockade of the AT 1 receptor [27] . As a corollary, Ang II-induced cardiac remodeling was suppressed in mice overexpressing brain natriuretic peptide (BNP) in the circulation, a member of the natriuretic peptide family which also activates the GC-A receptor, although with less affinity than ANP [43] . However, these studies could not distinguish between systemic and cardiac interactions of ANP/BNP and Ang II. Our study adds an important piece of information, because the conditional, cardiomyocyte-restricted disruption of the GC-A gene in mice allowed us to specifically dissect the local cardiac from the systemic interactions between the ANP/GC-A and Ang II/AT 1 systems. Furthermore, it characterizes PKG I and RGS2 as molecular effectors mediating the cross-talk between these pathways in cardiac remodeling. Our observation of a differential regulation of Ang II-but not b-adrenergic stimulation of myocyte calcium handling by ANP is in agreement with a study by Takimoto et al. [44] which also observed that b-adrenergic calcium and contractile responses of adult myocytes and intact hearts are unaffected by ANP/GC-A-elicited cGMP production at the plasma membrane. In contrast, nitric oxide (NO)-stimulated cGMP production in the cytosol (which is mediated by the soluble guanylyl cyclase, sGC), markedly blunted the cardiac contractile responses to ISO [44, 50] . Extending these observations, cardiac overexpression of endothelial NO synthase in transgenic mice attenuated cardiac hypertrophy induced by chronic ISO infusion [36] . Hence, these studies indicate that the NO/sGC/cGMP system acts as a negative modulator of both the cardiac contractile and hypertrophic responses to b-adrenergic stimulation [36, 44] . In contrast, the ANP/GC-A/cGMP system does not regulate these responses (present study and [44] ). In conclusion, our observations support the notion that cGMP synthesized by sGC (in response to NO) and membrane-bound GC-A (in response to ANP) does not feed a common cGMP pool in cardiac myocytes, but instead remains spatially and functionally compartmentalized to modulate different targets and thereby different myocyte functions.
Counteraction of the cardiac Ang II effects by ANP/GC-A/cGMP involves PKG I and RGS2
At least two cGMP-stimulated proteins (as third messengers) are expressed in myocytes: PKG I; and phosphodiesterase (PDE) 2, a dual substrate esterase, which appears to hydrolyze cGMP under resting conditions [2] , but targets cAMP in the presence of b-adrenergic stimulation [33] . In cultured endothelial cells, the ANP/GC-A/cGMP-signalling pathway stimulates PDE2 activity, decreases intracellular cAMP concentrations and thereby increases endothelial barrier functions [42] . However, in cardiomyocytes, the lack of effects of ANP on the calcium and inotropic responses to ISO (see present study and [44] ) suggests that PDE 2 activity is not modulated by the pool of cGMP formed after ANP/GC-A stimulation. This could be due to spatial compartmentalization or could be related to different concentrations of cGMP reached after GC-A stimulation in myocytes (expressing low levels of GC-A) when compared with endothelia (with very dense GC-A expression) [25, 26] .
Instead, using both a genetic and a pharmacological approach, our study demonstrates that PKG I is a downstream target activated by the ANP/GC-A/cGMP system in cardiomyocytes. As illustrated, the counter regulation of the Ca 2? responses of isolated adult myocytes to Ang II by ANP was absent in PKG I-deficient myocytes and also in wild-type myocytes pre-treated with the selective PKG I inhibitor, Rp-8-Br-PET-cGMP. However, the in vivo relevance of these in vitro findings has still to be demonstrated. Mice with a global deletion of PKG I show severe gastrointestinal dysfunction and high mortality before 6 weeks of age [38] . To circumvent these limitations, smooth muscle rescue mice were generated, in which PKG I expression is restored selectively in smooth muscle, but not in other cell types of PKG I null mice [49] . We used these rescue mice not only to isolate adult myocytes for our ex vivo calcium studies, but also to study the impact of PKG I deletion on the cardiac hypertrophic responses to chronic Ang II treatment. Ang II was administered for 14 days to eight 20-week-old male PKG I rescue mice and eight litter-matched control mice (300 ng Ang II/kg BW/ min with osmotic minipumps). Interestingly, the cardiac hypertrophic responses to Ang II were attenuated in the PKG I mutants when compared with control mice (data not shown). However, it is important to note that this group of rescue mice also showed a systemic phenotype. Unfortunately, these animals had anemia and splenomegalia [7] . In addition, and in contrast to the normal blood pressure of 10-week-old PKG I rescue mice [49] , we observed in the ''older'' rescue mice pronounced arterial hypotension (decreases in SBP by *20 mmHg measured by the tail cuff method, both before and during Ang II administration, data not shown). Thus, it is likely that the attenuated hypertrophic response of the PKG I mutants to Ang II is related to their systemic phenotype, especially to arterial hypotension. Hence, although our own and published data support an important protective role for myocardial PKG I in pathological cardiac hypertrophy in vivo [45] , a final proof is lacking.
At least in vitro several proteins centrally involved in myocyte calcium handling have been shown to be regulated by PKG I, such as the L-type Ca 2? channel (inhibition), phospholemman (inhibition) and phospholamban (inhibition, resulting in enhanced SR calcium uptake by SERCA) [6] . Our observation that the ANP/GC-A/cGMP/ PKG I pathway selectively inhibits the myocyte Ca 2? -responses to Ang II, but not to ISO, suggested a selective modulation of G aq/11 -coupled receptor signalling. The regulator of G protein signalling (RGS)-2 is a selective and negative regulator of G q/11 proteins in the cardiovascular system which is activated by PKG I [51] . For instance, in vascular smooth muscle cells the nitric oxide/ sGC/cGMP/PKG I pathway regulates the degradation of RGS2 and promotes its association with the plasma membrane by a mechanism requiring its PKG I phosphorylation sites [35] . By regulating RGS2 plasma membrane association and degradation, PKG I therefore may control its inhibitory effect on Gq/11-coupled receptors [35] . RGS2-deficient mice (RGS2 -/-) are hypertensive, exhibit increased vasoconstrictory responses to vasopressin and other hormones activating G q/11 -coupled receptors and diminished vasodilating responses to nitric oxide/ cGMP/PKG I signalling [14, 15, 35, 46] . Consistent with these observations, we found in the present study that the calcium responses of RGS2 -/-myocytes to Ang II were enhanced, whereas responses to b-adrenergic stimulation were unaltered. Notably, the inhibitory effect of ANP on calcium responses to Ang II was absent in RGS2 -/-myocytes. Concomitantly, in transfected HEK293 cells ANP, via GC-A/PKG I signalling, dramatically enhanced RGS2 expression and membrane localization. We conclude from these experiments that ANP, via GC-A/cGMP/ PKG I, enhances the expression and/or phosphorylation of RGS2 and thereby counteracts AngII/AT1 signalling. In turn, inhibition of ANP/GC-A signalling (in CM GC-A KO mice) enhances the cardiac hypertrophic responses to Ang II. Unfortunately for technical reasons, we could not complement these experiments with analyses of RGS2 expression and/or phosphorylation in wild type when compared with GC-A-or PKG I-deficient myocytes. There are no phospho-specific antibodies available. Worse, Western-blot analyses revealed that commercially available anti-RGS2 antibodies unspecifically recognize an immunoreactive protein of 28 kDa (the MW of RGS2) in tissues from both wild-type and RGS2-deficient mice (not shown). Hence, in our hands commercially available antibodies were unsuitable to study RGS2 expression in native tissues.
Collectively, our findings are compatible with the notion that PKG I is the downstream target activated by the ANP/ GC-A/cGMP-signalling pathway in cardiac myocytes. cGMP/PKG I-mediated modulation of RGS2 and subsequent inhibition of AT 1 /Gq-signalling appear to mediate the specific counter regulation of the calcium responses of myocytes to Ang II by ANP.
TRPC3/C6 channels are involved in the calcium responses of adult myocytes to Ang II Studies in neonatal rat cardiomyocytes have indicated that Ang II induces TRPC3/C6 activation through Gaq-phospholipase C (PLC) signalling pathways [34] . DAG, generated by PLC activation, directly activates TRPC3/C6 [17] . In neonatal myocytes, this causes slow depolarization of the membrane potential and concomitantly increases the frequency of spontaneous firing due to activation of L-type Ca 2? channel [34] . Indeed, in our study with adult murine ventricular myocytes, the effects of Ang II both on Ca 2? transients and on L-type Ca 2? currents were abolished in TRPC3/C6-deficient myocytes. In addition, BTP2, which inhibits the activity of TRPC channels [13] , abolished the calcium responses to Ang II.
Taken together these experiments demonstrate that TRPC channels are indispensable for the calcium responses of adult ventricular myocytes to Ang II. In contrast, b-adrenergic stimulation of Ca 2? currents and Ca 2? i handling was not altered by genetic or pharmacological blockade of TRPC channels. However, intriguingly, in whole-cell current-clamp recordings, we did not observe differences in the resting membrane potential of wild-type and TRPC3/C6-deficient myocytes or changes of the membrane potential in response to Ang II (data not shown). These unexpected findings point towards a novel mechanism of TRPC3/C6 activity regulating L-type Ca 2? channel (LTCC) activity in response to Ang II which we will try to elucidate in our future studies. One hypothesis is that TRPC-mediated Ca 2? entry activates CaMKII, which has been shown to be associated with cardiac LTCC complexes and increases channel open probability to dynamically increase Ca 2? current by a process called facilitation [10] .
Conclusion
Patients with cardiac hypertrophy and/or congestive heart failure have elevated plasma levels of ANP and BNP [25, 26] . However, the cardiovascular and cGMP responses to these hormones are markedly attenuated, indicating impaired receptor or post-receptor responsiveness of GC-A [25, 26] . Concurrently, the deleterious role of the local renin-angiotensin-aldosterone system in cardiac remodeling has been demonstrated by many experimental and clinical reports. Our study emphasizes that a disturbance of the delicate systemic and also local, cardiac balance between the ANP and RAA systems can critically contribute to the progression of cardiac hypertrophy.
